Pazopanib
- PDF / 157,371 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 76 Downloads / 175 Views
1
Pazopanib Hair and skin hypopigmentation: case report A 40-year-old woman developed hair and skin hypopigmentation during treatment with pazopanib for advanced, progressive thyroid cancer. The woman initially received oral pazopanib 800 mg/day continuously on a 28-day cycle. She experienced declining thyroglobulin tumour levels and developed a prompt Response Evaluation Criteria in Solid Tumours partial response. Concomitantly she experienced anorexia, hypertension, nausea, vomiting and diarrhoea, mild thrombocytopenia and leucopenia, and moderate asymptomatic hyperbilirubinaemia. Consequently her pazopanib dosage was reduced to 600 mg/day following the fourth cycle. After the second month of pazopanib therapy she developed progressive skin and hair hypopigmentation and hair thinning. Her skin continued to lighten during the first 12 months of therapy and she incurred a sunburn (grade 3) for the first time in her life during her eleventh month of therapy. [Patient follow-up and outcome not stated]. Sideras K, et al. Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib. Journal 803037142 of Clinical Oncology 28: e312-3, No. 19, Jul 2010 - USA
»
Editorial comment: Some details of this case have been previously published in an abstract [see Reactions 1309 p33; 3024083].
0114-9954/10/1318-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 11 Sep 2010 No. 1318
Data Loading...
